Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19-targeting CAR T Cell Therapy in the Treatment of Relapsed or Refractory CD19 Positive B-cell Malignancies

NCT03559439 is registered in ClinicalTrials.gov with Shanghai Tong Ren Hospital as lead sponsor.

NCT NCT03559439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03559439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19-targeting CAR T Cell Therapy in the Treatment of Relapsed or Refractory CD19 Positive B-cell Malignancies
Lead sponsor
Shanghai Tong Ren Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
April 24, 2018
Completion date
December 31, 2021
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukaemia, b-cell lymphoma, b-cell malignancy